Oxford Biomedica (LSE: OXB) delivers first EBITDA profit as revenue surges 33% and BMS CAR-T deal signals commercial maturity

Oxford Biomedica plc (LSE: OXB), the Oxford-headquartered cell and gene therapy contract development and manufacturing organisation, has reported full-year 2025 revenues of £168.7 million on a reported basis and £170.9 million in constant currency, representing 31% and 33% growth respectively over the £128.8 million recorded in fiscal 2024. The group achieved full-year operating EBITDA profitability for the first time in recent history, swinging from a loss of £15.3 million in 2024 to a profit of £8.1 million in constant currency, a milestone that management has characterised as validation of its pure-play CDMO strategy. The results were accompanied by a post-period commercial supply agreement with Bristol Myers Squibb for lentiviral vectors supporting BMS’ CAR-T programmes, a licensing agreement with an Australian viral vector manufacturer, and board approval for a further $15 million drawdown under the existing Oaktree Capital Management loan facility. OXB shares closed at 580p on 26 March 2026, up 4.29% on the day, with the 52-week range spanning a wide 232.50p to 950.00p, suggesting investors have been gradually pricing in a credibility recovery after years of loss-making operations.

How did Oxford Biomedica achieve its first full-year EBITDA profit and what does the underlying number reveal about the quality of the turnaround?

The headline constant-currency operating EBITDA of £8.1 million requires careful unpacking. Embedded within it is a one-off bargain purchase gain of £9.9 million arising from the accounting treatment of the Durham, North Carolina facility acquisition. Oxford Biomedica paid just $4.5 million (£3.3 million) for assets independently assessed at a fair value of $17.9 million (£13.3 million), the difference being recognised as a non-recurring gain under IFRS 3. Stripping that out, the underlying constant-currency operating EBITDA was £3.3 million, a more modest but still meaningful figure that confirms the business crossed the zero line on an organic basis for the first time. The operating loss at the statutory level narrowed sharply from £39.4 million in 2024 to £22.5 million in 2025, a £17 million improvement driven by the combination of revenue scale and what management describes as disciplined cost control. Net cash from operations turned positive at £0.5 million, compared with a £50.7 million outflow the prior year, a transformation that reflects not just improved profitability but a significant build in client deposits and upfront payments from clients securing manufacturing capacity into 2026.

The cost base expanded by 15% to £172.9 million, reflecting a 12% rise in manpower costs as headcount grew from 861 to 986 year-end employees, and a 22% increase in raw materials and external manufacturing costs tied directly to higher lentiviral vector batch volumes. Gross margin compressed modestly to 39% from 41%, the principal drag being a sharp increase in procurement and storage services, a lower-margin revenue line that grew nearly fivefold to £22.3 million from £5.8 million in 2024. While this diluted blended margins, procurement and storage revenues signal something strategically important: clients are using Oxford Biomedica to secure raw material supply chains ahead of commercial launches, indicating serious late-stage confidence in the group’s manufacturing reliability.

What does the Durham, North Carolina acquisition mean for Oxford Biomedica’s competitive position in the US viral vector market?

The Durham facility acquisition, completed in October 2025, stands as the year’s most consequential strategic move. Oxford Biomedica acquired a commercially-scaled, FDA-approved viral vector manufacturing site from RTP Operating LLC, a subsidiary of National Resilience Holdco Inc., for $4.5 million. The fair value of the acquired net assets was £13.3 million, making this an acquisition that would cost a competitor multiples more to replicate from scratch. The facility adds drug substance and fill-finish capabilities at commercial scale within the United States, the world’s largest cell and gene therapy market, which accounts for roughly half of all global viral vector programmes in development.

The strategic logic is straightforward: being physically present in the US with FDA-approved commercial capacity reduces regulatory friction, shortens supply chain timelines for American clients, and positions Oxford Biomedica to compete directly for programmes that previously would have required clients to accept transatlantic manufacturing. Oxford Biomedica’s Bedford, Massachusetts site has been refocused on operational excellence rather than capacity expansion, with Durham intended to become the commercial-scale AAV anchor in the US. A technology transfer from Bedford to Durham is underway to prepare the site for commercial AAV batch manufacturing, with fill-and-finish capability to follow. The integration generated £3.3 million in pre-tax losses in the period from acquisition to year-end, a transitional cost the group was transparent about, with the site expected to begin contributing meaningfully as Durham ramps through 2026.

Why is the revenue backlog and contracted order book significant for assessing Oxford Biomedica’s growth visibility into 2026 and 2027?

Revenue visibility is the structural advantage that pure-play CDMOs develop over time, and Oxford Biomedica’s forward indicators are now substantial. The revenue backlog, defined as future revenue available from current contracted orders, grew 36% to approximately £204 million at 31 December 2025 from approximately £150 million at the end of 2024. The contracted value of total client orders reached £224 million, up 20% from £186 million in 2024. More granularly, 60% of forecast 2026 revenues were covered by contracted client orders as at February 2026, with over 80% coverage when risk-adjusted pipeline is included. That degree of forward cover entering a financial year is unusual in the life sciences services sector and dramatically reduces execution uncertainty relative to earlier years when Oxford Biomedica was still establishing its commercial identity as a pure-play operator.

The pipeline of potential future revenues grew to $597 million at 31 December 2025 from $570 million at end-2024, despite a higher volume of orders being signed and converted out of pipeline during the year. The fact that new pipeline inflows outpaced order conversion is analytically important: it suggests that Oxford Biomedica’s commercial team is originating opportunities faster than the manufacturing business is executing them, the opposite problem to where the group was two years ago. AAV accounted for over half of new client wins during 2025, confirming that Oxford Biomedica’s diversification away from its lentiviral vector heritage is gaining real commercial traction.

How does the new Bristol Myers Squibb commercial supply agreement strengthen Oxford Biomedica’s position in the CAR-T manufacturing market?

The multi-year commercial supply agreement with Bristol Myers Squibb, signed in February 2026 following the close of the reporting period, is the highest-profile contract in Oxford Biomedica’s recent history. Under the agreement, Oxford Biomedica will manufacture and supply lentiviral vectors for BMS’s CAR-T therapy programmes. The strategic value of this contract extends well beyond its direct revenue contribution. Bristol Myers Squibb is one of the world’s largest pharmaceutical companies and a dominant force in the approved CAR-T market through its Breyanzi and ide-cel programmes. Being selected as a commercial supply partner by BMS is a reference account of the highest order, providing the sort of third-party validation that influences procurement decisions across the broader pharma and biotech client base.

Lentiviral vectors are the manufacturing backbone of most approved CAR-T therapies, and as those therapies move from single-site academic manufacturing to industrialised commercial production, the demand for high-volume, regulatory-grade lentiviral vector supply has intensified significantly. Oxford Biomedica’s lentiviral vector GMP manufacturing revenue grew 34% in the UK during 2025, the fastest-growing major segment within the group. The BMS agreement formalises Oxford Biomedica’s role in commercialisation at scale and will likely contribute to manufacturing services revenues beginning in 2026, providing a reliable revenue floor at the higher end of the margin spectrum.

What does Oxford Biomedica’s 2026 financial guidance tell investors about the pace of margin expansion and the risks of H1 weighting?

Oxford Biomedica has guided to constant-currency revenues of £220 to £240 million for 2026, implying approximately 30% to 42% growth over the reported 2025 figure, with an operating EBITDA margin of approximately 10%. For 2027 and 2028, the group targets 25% to 30% revenue growth annually with operating EBITDA margins rising to at least 20% by end-2027, with a long-term ambition approaching 30% over a five-to-six-year horizon from 2025. The capital expenditure guidance has also been revised downward to approximately £50 million in aggregate across 2026 and 2027, from a previously communicated £60 million, reflecting the capital efficiency provided by the Durham facility acquisition.

The 2026 revenue and EBITDA profile is explicitly described as second-half weighted, a disclosure that investors should take seriously. The first half of 2026 will absorb planned maintenance shutdowns, the completion of AAV and lentiviral technology transfers in France, and ongoing Durham integration costs. Management expects H1 2026 to be loss-making at the EBITDA level. The double-digit EBITDA margin anticipated for H2 2026 depends on three convergent factors: the successful GMP readiness of the AAV and lentiviral platforms at the French sites by the second quarter, the ramp-up of Durham revenues, and continued momentum in the existing UK manufacturing base. Should any of these technology transfers encounter delays, the H2 recovery could be deferred. This is the key execution risk for 2026.

How is Oxford Biomedica deploying artificial intelligence and digital transformation to improve manufacturing efficiency and client delivery timelines?

Oxford Biomedica has invested meaningfully in digitising its process development workflows during 2025, achieving complete digital data capture across the LentiVector platform. The group is building a data platform to automate visualisation and reporting across manufacturing operations, with machine learning integration planned to drive predictive analytics. Its Design of Experiments optimisation services, which combine machine learning with automation to identify optimal experimental conditions, delivered approximately 100 hours of time savings per plasmid ratio study, an 80% reduction in study duration, while simultaneously increasing product yields. The group is also developing hybrid AI models for predictive modelling, which aim to forecast experimental outcomes before physical testing begins, compressing development timelines and reducing cost.

These investments are not merely operational housekeeping. In viral vector manufacturing, batch failure is expensive and time-sensitive, and predictive tools that reduce failure rates or allow earlier identification of out-of-specification batches translate directly into client confidence and gross margin resilience. Oxford Biomedica’s growing use of cellular potency assays, which engage clients early in the development process to streamline regulatory submissions, is a differentiation strategy aimed at reducing the time and cost burden on clients navigating regulatory pathways. For a business targeting margin expansion from current single-digit levels toward 20% and beyond, operational leverage through automation and digitalisation is a prerequisite, not an option.

What are the key balance sheet and liquidity considerations as Oxford Biomedica scales its global manufacturing network through 2027?

Oxford Biomedica ended 2025 with cash and cash equivalents of £96.9 million, up from £60.7 million at end-2024, and net cash of £55.4 million compared with £20.6 million the prior year. The improvement was funded primarily by the August 2025 equity raise of approximately £60 million at £4.31 per share and the refinancing of the existing Oaktree facility into a new four-year, $125 million senior secured loan, of which $60 million was immediately drawn. The loan matures in August 2029 and carries a floating rate set at 7% above the three-month SOFR, floored at 9%, with a payment-in-kind option for the first two years. An interest rate cap agreement has been entered into to limit upside rate exposure.

Lease liabilities totalled £106.6 million at year-end, up significantly from £68.7 million the prior year, reflecting the Durham facility lease addition. Net finance costs grew to £9.5 million from £7.9 million, driven by higher lease interest charges following the Oxbox rent review, the Yarnton lease renewal, and the inclusion of Durham lease costs from the fourth quarter. The Board has also approved a further $15 million drawdown under the Oaktree facility in March 2026, bringing total drawn debt closer to the facility limit for working capital. The going concern assessment is clear, with the group demonstrating that it can meet all liabilities for at least twelve months and that loan covenants would be maintained even in severe downside scenarios without requiring mitigating action until at least the end of Q3 2026.

How is the OXB share price responding to the FY2025 results and what does the current valuation imply about market expectations?

Oxford Biomedica shares closed at 580p on 26 March 2026, up 4.29% on the day, a positive but measured market reaction to a results announcement that broadly met or exceeded expectations on the key operating EBITDA milestone. The 52-week range of 232.50p to 950.00p tells its own story: the stock recovered aggressively from deep lows as commercial momentum accumulated, before retracing from the upper end as investors weighed H1 2026 loss guidance. At 580p against analyst consensus price targets around 700p to 882p, Oxford Biomedica trades at what the market appears to view as a credibility discount, with the premium being withheld until management demonstrates that the technology transfer execution in France and the Durham ramp materialise on schedule in the second half of 2026.

The market capitalisation at 580p implies approximately £700 million, against a revenue run rate heading toward £220 to £240 million in 2026. On an enterprise value basis, incorporating net cash and lease obligations, the implied revenue multiple is relatively modest for a cell and gene therapy CDMO with contracted forward visibility of this quality. Peer CDMOs operating at comparable scales and margins trade at significantly higher multiples. The re-rating thesis depends entirely on whether Oxford Biomedica can demonstrate that the margin expansion toward 20% EBITDA by 2027 is achievable without major execution stumbles, particularly on the French technology transfer timeline which is the most tangible near-term milestone.

Key takeaways: What Oxford Biomedica’s FY2025 results mean for the cell and gene therapy CDMO sector and its competitors

• Oxford Biomedica achieved full-year operating EBITDA profitability in constant currency for the first time in recent history, but the underlying figure of £3.3 million after removing the Durham bargain purchase gain signals a business that is profitable but not yet generating meaningful cash surplus from operations.
• The Durham, North Carolina acquisition at $4.5 million for assets valued at $17.9 million represents one of the most capital-efficient facility additions in the CDMO sector in recent years, establishing FDA-approved commercial-scale capacity in the world’s largest viral vector market at a fraction of greenfield cost.
• The BMS commercial supply agreement for CAR-T lentiviral vectors is a reference-quality contract that validates Oxford Biomedica’s manufacturing credibility at the highest level of the pharma industry and will influence competitor procurement decisions.
• Revenue backlog of £204 million and contracted orders of £224 million entering 2026, with over 80% revenue coverage including risk-adjusted pipeline, represent exceptional forward visibility for a mid-cap life sciences services business.
• AAV represented over half of new client wins during 2025, demonstrating that Oxford Biomedica has successfully extended its commercial reach beyond its lentiviral vector heritage into the broader viral vector market, with the pipeline at $597 million and growing.
• The 2026 H1 EBITDA loss guidance is the critical near-term risk: investors pricing in a smooth recovery will be tested by planned shutdowns, Durham integration costs, and technology transfer completion fees in the French sites before any double-digit H2 margin materialises.
• The Oaktree loan refinancing from $50 million to a $125 million facility maturing in 2029 removes an imminent 2026 repayment risk and provides capacity for strategic acquisitions via a dedicated $25 million delayed tranche, extending the strategic optionality of the balance sheet.
• Gross margin compression to 39% from 41% reflects the mix shift toward procurement and storage services, a necessary but lower-margin activity that signals client maturity and commercial readiness rather than pricing pressure, and should partially reverse as commercial manufacturing revenue scales.
• Competitors in the viral vector CDMO space, including Lonza, Catalent, and Samsung Biologics’ CGT unit, face a company that is now demonstrably profitable, US-present at commercial scale, and backed by BMS as a reference client, raising the competitive bar materially.
• The APAC licensing agreement with Australian CDMO Viral Vector Manufacturing Facility extends Oxford Biomedica’s platform reach without balance sheet commitment, an asset-light approach to capturing growth in a fast-expanding regional market.